Shield TherapeuticsSTU:1JS EBIT per Share is €-0.01 as of Dec. 2025. The stock has 5 warning signs investors should review. Among 808 Drug Manufacturers companies, Shield Therapeutics ranks better than 92.33% on this metric.
Shield Therapeutics's EBIT per Share for the
six
months ended in Dec. 2025 was €-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.01.
During the past 3 years, the average EBIT per Share Growth Rate was 60.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 25.60% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 20.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Shield Therapeutics's EBIT per Share or its related term are showing as below:
STU:1JS'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -32.9 Med: 14 Max: 60.2
Current: 60.2
During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Shield Therapeutics was 60.20% per year. The lowest was -32.90% per year. And the median was 14.00% per year.
STU:1JS's 3-Year EBIT Growth Rate is ranked better than 92.33% of 808
companies
in the Drug Manufacturers industry
Industry Median: 7.65
vs STU:1JS: 60.20
Shield Therapeutics (STU:1JS) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Shield Therapeutics EBIT per Share Related Terms
Shield Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Shield Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shield Therapeutics (STU:1JS) has a EBIT per Share of €-0.01 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Shield Therapeutics and its competitors. According to the industry distribution chart, Shield Therapeutics ranks #62 out of 808 companies in the Drug Manufacturers industry, placing it in the top 7.7%.
Is Shield Therapeutics' EBIT per Share too high?
Shield Therapeutics' current EBIT per Share is €-0.01. Based on the distribution chart, Shield Therapeutics ranks #62 out of 808 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Shield Therapeutics' EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shield Therapeutics ranks #62 out of 808 companies for EBIT per Share. This places Shield Therapeutics in the top 8% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.65, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Shield Therapeutics and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shield Therapeutics's current EBIT per Share is €-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (STU:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.10, compared to a current price of €0.07 — trading 32% below its estimated fair value. The current EBIT per Share is €-0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Shield Therapeutics (STU:1JS), the current EBIT per Share is €-0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1JS has been successfully added to your 